NCT01687218View on ClinicalTrials.gov

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

September 25, 2013

Primary Completion Date

May 26, 2015

Study Completion Date

May 26, 2015

Conditions
HIV
Interventions
DRUG

Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)

DRUG

Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)

DRUG

Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)

Trial Locations (8)

11000

Thailand MOPH - US CDC Collaboration (TUC), Nonthaburi

15213

University of Pittsburgh Medical Center (UPMC), Pittsburgh

50202

Research Institute for Health Sciences - Chiang Mai University, Chiang Mai

94102

HIV Research Section, San Francisco - Department of Public Health, San Francisco

02115

The Fenway Institute/Fenway Community Health, Boston

Unknown

Asociacion Civil Impacta Salud y Educacion (IMPACTA), Lima

Desmond Tutu HIV Foundation, Cape Town

00936-5067

University of Puerto Rico Medical Sciences Campus - Maternal Infant Studies Center (CEMI), San Juan

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

CONRAD

OTHER

NCT01687218 - Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel | Biotech Hunter | Biotech Hunter